A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 231,500 shares of BBIO stock, worth $6.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
231,500
Previous 313,000 26.04%
Holding current value
$6.6 Million
Previous $7.93 Million 25.67%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$23.91 - $31.3 $18.8 Million - $24.6 Million
785,665 Added 36.43%
2,942,114 $74.9 Million
Q2 2024

Aug 14, 2024

BUY
$23.0 - $31.04 $29.3 Million - $39.5 Million
1,273,174 Added 144.14%
2,156,449 $54.6 Million
Q1 2024

May 15, 2024

BUY
$27.35 - $40.45 $5.99 Million - $8.86 Million
219,120 Added 32.99%
883,275 $27.3 Million
Q4 2023

Feb 14, 2024

BUY
$24.02 - $43.89 $2.29 Million - $4.19 Million
95,495 Added 16.79%
664,155 $26.8 Million
Q3 2023

Nov 14, 2023

BUY
$16.89 - $35.01 $2.62 Million - $5.43 Million
155,050 Added 37.49%
568,660 $15 Million
Q2 2023

Aug 14, 2023

BUY
$13.29 - $18.01 $1.69 Million - $2.29 Million
126,878 Added 44.25%
413,610 $7.11 Million
Q1 2023

May 15, 2023

SELL
$7.17 - $18.55 $18.6 Million - $48.1 Million
-2,590,456 Reduced 90.03%
286,732 $4.75 Million
Q4 2022

Feb 14, 2023

BUY
$6.74 - $11.52 $7.19 Million - $12.3 Million
1,066,176 Added 58.87%
2,877,188 $21.9 Million
Q3 2022

Nov 14, 2022

BUY
$7.94 - $12.36 $7.7 Million - $12 Million
969,218 Added 115.14%
1,811,012 $18 Million
Q2 2022

Aug 15, 2022

BUY
$5.21 - $12.14 $2.37 Million - $5.53 Million
455,732 Added 118.05%
841,794 $7.64 Million
Q1 2022

May 16, 2022

BUY
$7.34 - $17.16 $319,392 - $746,700
43,514 Added 12.7%
386,062 $3.92 Million
Q3 2021

Nov 15, 2021

SELL
$46.87 - $64.24 $3.28 Million - $4.5 Million
-70,030 Reduced 16.97%
342,548 $16.1 Million
Q2 2021

Aug 16, 2021

BUY
$46.47 - $63.93 $10.6 Million - $14.5 Million
227,093 Added 122.43%
412,578 $25.2 Million
Q1 2021

May 17, 2021

SELL
$55.47 - $72.35 $2.71 Million - $3.53 Million
-48,798 Reduced 20.83%
185,485 $11.4 Million
Q4 2020

Feb 16, 2021

BUY
$38.38 - $71.11 $4.63 Million - $8.58 Million
120,665 Added 106.2%
234,283 $16.7 Million
Q3 2020

Nov 16, 2020

BUY
$27.2 - $42.19 $1.81 Million - $2.81 Million
66,634 Added 141.82%
113,618 $4.26 Million
Q2 2020

Aug 14, 2020

BUY
$22.22 - $35.69 $324,767 - $521,645
14,616 Added 45.16%
46,984 $1.53 Million
Q1 2020

May 15, 2020

BUY
$16.11 - $36.23 $162,501 - $365,452
10,087 Added 45.27%
32,368 $939,000
Q2 2019

Aug 14, 2019

BUY
$26.97 - $27.55 $600,918 - $613,841
22,281 New
22,281 $601,000

Others Institutions Holding BBIO

About BridgeBio Pharma, Inc.


  • Ticker BBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 148,246,000
  • Market Cap $4.23B
  • Description
  • BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...
More about BBIO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.